Motus GI (MOTS)

Executive Summary

Motus GI Holdings, Inc. is a medical technology company addressing inadequate bowel preparation during colonoscopy and upper GI endoscopy, a persistent problem affecting procedure quality and patient outcomes. Its flagship Pure-Vu® System is an FDA-cleared and CE-marked device that enhances visualization by cleansing the GI tract in real-time, reducing the need for repeat procedures and improving diagnostic accuracy. The system is designed for hospitals and endoscopy centers, targeting a large unmet need as poor preparation affects up to 25% of colonoscopies, leading to missed lesions and increased costs. Founded in 2011 and headquartered in Fort Lauderdale, Florida, the company is publicly traded (NASDAQ: MOTS) and leverages a focused commercial strategy to drive adoption in the U.S. and Europe. Despite a proven product, Motus GI faces challenges in scaling commercialization and achieving consistent revenue growth. Recent efforts have centered on expanding clinical evidence, securing key opinion leader endorsements, and building a direct sales force. The company's valuation of approximately $638 million reflects optimism for its technology but also the risks of a competitive market and capital-intensive sales cycle. Key near-term catalysts include potential FDA clearance for an expanded upper GI indication, which could broaden the addressable market, and the potential for strategic partnerships or distribution agreements to accelerate market penetration. Investors should monitor adoption metrics, reimbursement developments, and upcoming clinical data presentations, which will be critical to the company's trajectory.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for Pure-Vu System in upper GI endoscopy70% success
• Q4 2026Strategic partnership or distribution agreement with a major GI hospital network or GPO60% success
• Q4 2026Presentation of positive clinical outcomes data at a major gastroenterology conference (e.g., ACG or DDW)80% success